Side-by-side · Research reference
CerebrolysinvsPEG-MGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED11/65 cited
BAnimal-MechanisticHUMAN-REVIEWED2/69 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
01Mechanism of Action
Parameter
Cerebrolysin
PEG-MGF
Primary target
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
IGF-1 receptor on muscle satellite cells and myocytes
Pathway
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
Downstream effect
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Feedback intact?
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
Partially bypassed — does not require hepatic IGF-1 synthesis
Origin
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Antibody development
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
Unknown — no long-term human immunogenicity data
02Dosage Protocols
Parameter
Cerebrolysin
PEG-MGF
Standard dose (stroke)
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
—
Lower dose (dementia)
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
—
Duration
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
—
Timing (stroke)
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
—
Adjunct to thrombectomy
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
—
Evidence basis
Phase 3 RCT + observational
Animal / mechanistic
Administration route
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
—
Research dose range
—
100–200 mcg
Extrapolated from animal models; no validated human protocols.
Frequency
—
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Half-life
—
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
Reconstitution
—
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
PEG molecular weight
—
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
Timing
—
Within 30–60 min post-training
Aligns with endogenous MGF window.
03Metabolic / Fat Loss Evidence
Parameter
Cerebrolysin
PEG-MGF
Primary target
—
Muscle tissue (satellite cells, myocytes) — not adipose-specific
Indirect metabolic effect
—
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
Body composition
—
Lean mass preservation / hypertrophy focus
Fat loss evidence
—
No direct human or animal RCT data for PEG-MGF-driven fat reduction
04Side Effects & Safety
Parameter
Cerebrolysin
PEG-MGF
Injection site reaction
Mild pain, erythema (IM route)
Erythema, induration (common with SQ peptides)
Infusion reaction
Rare: flushing, transient hypotension during rapid IV
—
Agitation / Restlessness
Reported in <5% of patients; typically mild, self-limited
—
Serious adverse events
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
—
Hemorrhagic transformation
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
—
Mortality
No increase; meta-analysis RR 0.89 (0.68-1.18)
—
Allergic reaction
Rare; porcine origin theoretically immunogenic but clinically insignificant
—
Seizure risk
Not elevated; safe in epilepsy populations
—
Hypoglycemia risk
—
IGF-1 axis activation can lower blood glucose
IGF-1R overstimulation
—
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
Fluid retention
—
Possible with IGF-1 pathway activation (dose-dependent)
PEG accumulation
—
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
Antibody formation
—
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
Cancer risk
—
IGF-1 axis stimulation contraindicated in active malignancy
Human safety data
—
Absent — no published human trials for PEG-MGF
Absolute Contraindications
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Relative Contraindications
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
05Administration Protocol
Parameter
Cerebrolysin
PEG-MGF
1. Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
2. Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
3. IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
4. Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
5. Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
6. Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
—
06Stack Synergy
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair